Press Releases

EMERYVILLE, Calif., November 25, 2024 — Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today announced its participation in the 2024 Personalized Cancer Vaccine Summit, which includes a talk by Chief Scientific Officer Sam Deutsch, Ph.D. The event, which is taking place from December 3-5 in […]

EMERYVILLE, Calif., November 12, 2024 — Nutcracker Therapeutics, Inc., a pioneering biotechnology company dedicated to enabling transformative RNA therapies through its proprietary technology platform, today announced its new contract research, development, and manufacturing organization (CRDMO) capabilities, which will provide next-generation design and biomanufacturing solutions for RNA drug developers. Nutcracker Therapeutics’ manufacturing solutions can be scaled […]

EMERYVILLE, Calif., August 7, 2024 – Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today announced the publication of its latest peer-reviewed paper, which explores the fundamental aspects of its Nutshell® platform of peptoid-based mRNA delivery vehicles. The paper, published in ACS Nano, outlines the design […]

EMERYVILLE, Calif., June 5, 2024 – Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, recently presented a poster on NTX-472, its new preclinical drug candidate for B cell lymphoma, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Monoclonal antibody immunotherapies can […]

EMERYVILLE, Calif., May 15, 2024 – Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today announced it will introduce its new preclinical drug candidate, NTX-472, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago from May 31 to June 4. […]

EMERYVILLE, Calif., May 15, 2024 – Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today detailed data presented by its partners at the University of California, San Francisco (UCSF) on foundational prostate cancer antigen research utilized to inform the development of its mRNA drug candidate, NTX-470. […]

EMERYVILLE, Calif., April 11, 2024 – Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, recently presented two posters at the American Association for Cancer Research (AACR) Annual Meeting in San Diego: one showcasing the latest preclinical data for the company’s mRNA drug candidate for prostate cancer, […]

EMERYVILLE, Calif., March 12, 2024 – Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today announced that two poster presentations highlighting the company’s RNA therapeutics pipeline will be introduced at the 2024 American Association for Cancer Research (AACR) Annual Meeting. The first presentation entails LIGHT, an […]

EMERYVILLE, Calif., January 8, 2024 — Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary platform, today announced the promotion of Samuel Deutsch, Ph.D., as the company’s chief scientific officer (CSO). Dr. Deutsch has been a part of the Nutcracker team since its inception, and previously served as its […]